Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 4/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | PTGIR | P43119 | 1/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13396478 | 0.94 | PTGS1 (0.40) | PTGS1PTGS2LTA4HALOX5FDFT1 | |
| SCHEMBL13396460 | 0.89 | ALOX5 (0.39) | PTGS1PTGS2ALOX5FDFT1PPARG | |
| SCHEMBL13396512 | 0.88 | ACHE (0.40) | PTGS1PTGS2LTA4HALOX5 | |
| SCHEMBL13396358 | 0.87 | ALOX5 (0.42) | PTGS1PTGS2ALOX5FDFT1PPARG | |
| SCHEMBL13396473 | 0.87 | FFAR1 (0.42) | PTGS2LTA4HFFAR1CYP4F2CYP4A11 | |
| SCHEMBL13396514 | 0.86 | ALOX5 (0.39) | PTGS1PTGS2ALOX5FDFT1 | |
| SCHEMBL13396433 | 0.86 | ALOX5 (0.39) | PTGS1PTGS2ALOX5 | |
| SCHEMBL13416630 | 0.83 | LTA4H (0.39) | LTA4HFDFT1FFAR1PPARGPPARA | |
| SCHEMBL13396490 | 0.83 | ALOX5 (0.40) | PTGS1PTGS2LTA4HALOX5FFAR1 | |
| SCHEMBL13396392 | 0.82 | MTNR1A (0.38) | ALOX5FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266820-B2 | Nitric oxide donor compounds | NICOX SCIENCE IRELAND (IE) | 2016-02-23 | — | — | US | disclosed |
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SA (FR) | 2014-09-25 | — | — | US | disclosed |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | PTGS1 8/4885PTGS2 15/4885LTA4H 1170/4885 |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | PTGS1 7/4885PTGS2 12/4885LTA4H 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.